Seetharamu N - Search Results

1

Lorlatinib induced proteinuria: A case report.

Lee CS, Wanchoo R, Seetharamu N. Lee CS, et al. Among authors: seetharamu n. J Oncol Pharm Pract. 2021 Jun;27(4):1037-1039. doi: 10.1177/1078155220961549. Epub 2020 Sep 30. J Oncol Pharm Pract. 2021. PMID: 32996364

2

Impact of Tyrosine Kinase Inhibitor Starting Dose on Outcomes in Patients With Non-Small Cell Lung Cancer.

Miao E, Seetharamu N, Sullivan K, Eng S, Lee CS. Miao E, et al. Among authors: seetharamu n. J Pharm Pract. 2021 Feb;34(1):11-16. doi: 10.1177/0897190019840596. Epub 2019 Jun 5. J Pharm Pract. 2021. PMID: 31167592

3

Hyperpigmentation due to imatinib: A rare case of cutaneous involvement.

Rehman H, Hakim N, Sugarman R, Seetharamu N, Saif MW. Rehman H, et al. Among authors: seetharamu n. J Oncol Pharm Pract. 2020 Sep;26(6):1511-1515. doi: 10.1177/1078155220903364. Epub 2020 Feb 18. J Oncol Pharm Pract. 2020. PMID: 32067560

4

Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer.

Lee CS, Devoe CE, Zhu X, Fishbein JS, Seetharamu N. Lee CS, et al. Among authors: seetharamu n. Lung Cancer Manag. 2020 Apr 24;9(2):LMT31. doi: 10.2217/lmt-2020-0008. Lung Cancer Manag. 2020. PMID: 32346405 Free PMC article.

5

Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer.

Singh N, Seetharamu N. Singh N, et al. Among authors: seetharamu n. BMJ Case Rep. 2020 Aug 24;13(8):e236101. doi: 10.1136/bcr-2020-236101. BMJ Case Rep. 2020. PMID: 32843385 Free PMC article.

6

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity.

Lee CS, Sharma S, Miao E, Mensah C, Sullivan K, Seetharamu N. Lee CS, et al. Among authors: seetharamu n. Lung Cancer (Auckl). 2020 Oct 7;11:73-103. doi: 10.2147/LCTT.S258444. eCollection 2020. Lung Cancer (Auckl). 2020. PMID: 33117017 Free PMC article. Review.

7

Epidemiology and clinicopathological features of lung cancer in patients with prior history of breast cancer.

Wang KY, Newman J, Lee CS, Seetharamu N. Wang KY, et al. Among authors: seetharamu n. SAGE Open Med. 2021 May 25;9:20503121211017757. doi: 10.1177/20503121211017757. eCollection 2021. SAGE Open Med. 2021. PMID: 34104436 Free PMC article. Review.

8

A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study.

Lee CS, Ahmed I, Miao E, Chung S, Patel K, Kohn N, Seetharamu N. Lee CS, et al. Among authors: seetharamu n. J Oncol Pharm Pract. 2022 Jul;28(5):1140-1151. doi: 10.1177/10781552211020798. Epub 2021 Jun 13. J Oncol Pharm Pract. 2022. PMID: 34120514

9

Clinical efficacy with dabrafenib and trametinib in a T599_V600insT poorly differentiated metastatic thyroid carcinoma.

Lee CS, Miao E, Das K, Seetharamu N. Lee CS, et al. Among authors: seetharamu n. BMJ Case Rep. 2021 Aug 19;14(8):e243264. doi: 10.1136/bcr-2021-243264. BMJ Case Rep. 2021. PMID: 34413035 Free PMC article.

10

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data.

Lee CS, Milone M, Seetharamu N. Lee CS, et al. Among authors: seetharamu n. Onco Targets Ther. 2021 Aug 26;14:4579-4597. doi: 10.2147/OTT.S227032. eCollection 2021. Onco Targets Ther. 2021. PMID: 34471361 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters